

Title (en)  
CRYSTALLINE FORM F OF ATORVASTATIN HEMI-CALCIUM SALT

Title (de)  
KRISTALLINE FORM F VON ATORVASTATIN HEMI CALCIUM SALZ

Title (fr)  
FORME CRISTALLINE DU SEL HEMI CALCIQUE DE L'ATORVASTATINE

Publication  
**EP 1572643 A2 20050914 (EN)**

Application  
**EP 03812471 A 20031126**

Priority

- EP 03812471 A 20031126
- EP 02406037 A 20021128
- EP 03405110 A 20030220
- US 0338090 W 20031126

Abstract (en)  
[origin: WO2004050618A2] The present invention is directed to the novel polymorphic Form F of Atorvastatin calcium, processes for the preparation thereof and pharmaceutical compositions comprising this crystalline form.

IPC 1-7  
**C07D 207/34; A61K 31/40**

IPC 8 full level  
**A61K 31/40** (2006.01); **C07D 207/34** (2006.01)

CPC (source: EP)  
**A61P 3/06** (2017.12); **C07D 207/34** (2013.01)

Citation (search report)  
See references of WO 2004050618A2

Citation (examination)

- WO 2004043918 A2 20040527 - TEVA PHARMA [IL], et al
- CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE LNKD- DOI:10.1007/3-540-69178-2\_5, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2004050618 A2 20040617; WO 2004050618 A3 20040715; WO 2004050618 A8 20050714**; AU 2003297594 A1 20040623; AU 2003297594 A8 20040623; CA 2508871 A1 20040617; CA 2508871 C 20080909; EP 1572643 A2 20050914

DOCDB simple family (application)  
**US 0338090 W 20031126**; AU 2003297594 A 20031126; CA 2508871 A 20031126; EP 03812471 A 20031126